These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33194682)

  • 1. Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma
    Wu H; Zhang XY; Niu M; Li FF; Gao S; Wei W; Li SW; Zhang XD; Liu SL; Pang D
    Front Oncol; 2020; 10():574552. PubMed ID: 33194682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Théberge I; Vandal N; Guertin MH; Perron L
    Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicopathological study of fibroadenomas with epithelial proliferation including lobular carcinoma in-situ, atypical ductal hyperplasia, DCIS and invasive carcinoma.
    Krishnamurthy K; Alghamdi S; Gyapong S; Kaplan S; Poppiti RJ
    Breast Dis; 2019; 38(3-4):97-101. PubMed ID: 30909180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Woo JW; Choi HY; Kim M; Chung YR; Park SY
    Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study.
    Rohan TE; Ginsberg M; Wang Y; Couch FJ; Feigelson HS; Greenlee RT; Honda S; Stark A; Chitale D; Wang T; Xue X; Oktay MH; Sparano JA; Loudig O
    BMJ Open; 2021 Oct; 11(10):e053397. PubMed ID: 34702732
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sieuwerts AM; Doebar SC; de Weerd V; Verhoef EI; Beauford CM; Agahozo MC; Martens JWM; van Deurzen CHM
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene.
    Balatti V; Oghumu S; Bottoni A; Maharry K; Cascione L; Fadda P; Parwani A; Croce C; Iwenofu OH
    Head Neck Pathol; 2019 Sep; 13(3):344-354. PubMed ID: 30259272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer.
    Gram EG; Manso TFR; Heleno B; Siersma V; Á Rogvi J; Brodersen JB
    Breast; 2023 Aug; 70():41-48. PubMed ID: 37307773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.
    Bergholtz H; Lien TG; Swanson DM; Frigessi A; ; Daidone MG; Tost J; Wärnberg F; Sørlie T
    NPJ Breast Cancer; 2020; 6():26. PubMed ID: 32577501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of stage-specific breast markers using quantitative proteomics.
    Shaheed SU; Rustogi N; Scally A; Wilson J; Thygesen H; Loizidou MA; Hadjisavvas A; Hanby A; Speirs V; Loadman P; Linforth R; Kyriacou K; Sutton CW
    J Proteome Res; 2013 Dec; 12(12):5696-708. PubMed ID: 24106833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
    Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
    JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ and invasive carcinoma originating in a Fibroadenoma with concurrent benign phyllodes tumor: A case report.
    Ahmad A; Najeeb E; Ul Haq MB; Bashir H; Uzair M; Mamoon N
    Int J Surg Case Rep; 2024 Mar; 116():109196. PubMed ID: 38368667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
    Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
    Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
    Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.